These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16312501)

  • 1. Amoxycillin/clavulanic acid levels in respiratory secretions.
    Reid TM; Gould IM; Legge JS
    J Chemother; 1989 Jul; 1(4 Suppl):496-8. PubMed ID: 16312501
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral bioavailability and pharmacokinetic profile of the amoxicillin-clavulanic acid combination after intravenous and oral gavage administration in broiler chickens.
    Jerzsele A; Nagy G; Lehel J; Semjen G
    J Vet Pharmacol Ther; 2009 Oct; 32(5):506-9. PubMed ID: 19754920
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying.
    Weitschies W; Friedrich C; Wedemeyer RS; Schmidtmann M; Kosch O; Kinzig M; Trahms L; Sörgel F; Siegmund W; Horkovics-Kovats S; Schwarz F; Raneburger J; Mönnikes H
    Eur J Pharm Biopharm; 2008 Oct; 70(2):641-8. PubMed ID: 18582572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
    File TM
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S131-4. PubMed ID: 18029151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetration of augmentin and timentin into lymph after simulation of human serum pharmacokinetics in the rabbit.
    Woodnutt G; Kernutt I; Mizen L
    J Chemother; 1989 Jul; 1(4 Suppl):477-8. PubMed ID: 16312492
    [No Abstract]   [Full Text] [Related]  

  • 7. Ciprofloxacin versus amoxycillin/clavulanic acid in the treatment of urinary tract infections in general practice.
    Abbas AM; Chandra V; Dongaonkar PP; Goel PK; Kacker P; Patel NA; Shrivastava OP; Thakkar B; Tillotson GS
    J Chemother; 1989 Jul; 1(4 Suppl):858-9. PubMed ID: 16312672
    [No Abstract]   [Full Text] [Related]  

  • 8. Three vs. 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study.
    Roede BM; Bresser P; El Moussaoui R; Krouwels FH; van den Berg BT; Hooghiemstra PM; de Borgie CA; Speelman P; Bossuyt PM; Prins JM
    Clin Microbiol Infect; 2007 Mar; 13(3):284-90. PubMed ID: 17391383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and clinical studies on timentin in ear, nose and throat infections.
    Federspil P; Koch A; Schedler M; Tiesler E
    J Chemother; 1989 Jul; 1(4 Suppl):500-1. PubMed ID: 16312503
    [No Abstract]   [Full Text] [Related]  

  • 10. [A randomized study comparing amoxicillin-clavulanic acid with cefazolin as antimicrobial prophylaxis in laparotomic gynecologic surgery].
    Scardigno D; Lavermicocca T; Magazino MP; Cazzolla A; Lorusso M; Vicino M
    Minerva Ginecol; 2006 Apr; 58(2):85-90. PubMed ID: 16582864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy.
    Salvo F; Polimeni G; Moretti U; Conforti A; Leone R; Leoni O; Motola D; Dusi G; Caputi AP
    J Antimicrob Chemother; 2007 Jul; 60(1):121-6. PubMed ID: 17449881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of amoxicillin and clavulanate degradation alone and in combination in aqueous solution under frozen conditions.
    Vahdat L; Sunderland VB
    Int J Pharm; 2007 Sep; 342(1-2):95-104. PubMed ID: 17592747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS; Jacobs MR; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis.
    Chierakul W; Wangboonskul J; Singtoroj T; Pongtavornpinyo W; Short JM; Maharjan B; Wuthiekanun V; Dance DA; Teparrukkul P; Lindegardh N; Peacock SJ; Day NP; Chaowagul W; White NJ
    J Antimicrob Chemother; 2006 Dec; 58(6):1215-20. PubMed ID: 17003061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute localized exanthematous pustulosis (ALEP) caused by amoxicillin-clavulanic acid.
    Betto P; Germi L; Bonoldi E; Bertazzoni M
    Int J Dermatol; 2008 Mar; 47(3):295-6. PubMed ID: 18289337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kounis syndrome secondary to amoxicillin/clavulanic acid use.
    Tavil Y; Turfan M; Türkoğlu S; Abaci A
    Int J Cardiol; 2008 Feb; 124(1):e4-7. PubMed ID: 17360053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amoxycillin/clavulanic acid levels in lower respiratory secretions.
    Gould IM; Legge JS; Reid TM
    J Antimicrob Chemother; 1988 Jul; 22(1):88-90. PubMed ID: 3170397
    [No Abstract]   [Full Text] [Related]  

  • 18. Amoxicillin-clavulanic acid-induced linear immunoglobulin A bullous dermatosis: case report and review of the literature.
    Panasiti V; Rossi M; Devirgiliis V; Curzio M; Bottoni U; Calvieri S
    Int J Dermatol; 2009 Sep; 48(9):1006-10. PubMed ID: 19702992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction: historical perspective and development of amoxicillin/clavulanate.
    Geddes AM; Klugman KP; Rolinson GN
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S109-12. PubMed ID: 17900874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.